{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-211456","form_type":"8-K","ticker":"TSHA","cik":"0001806310","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.332142+00:00","generated_at":"2026-06-11T12:18:57.633026+00:00","sec_items":["1.01","2.02","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Taysha raises $150M PIPE; first Rett patient data shows clinical improvement","bullets":["Gross proceeds of $150M from PIPE: 122.4M shares at $0.90/share and 44.3M pre-funded warrants.","Q2 2023 net loss $24.6M ($0.38/sh); cash $45.1M at June 30; PIPE extends runway into Q3 2025.","First adult Rett patient dosed in REVEAL trial: TSHA-102 well-tolerated, no SAEs at 6 weeks.","At 4 weeks, CGI-I score of 2 (much improved), RSBQ improved 23 points, patient gained ability to sit unassisted and hold objects.","FDA cleared IND for TSHA-102 in pediatric Rett; CTA submitted to UK MHRA."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-211456","json":"https://secwatch.observer/filing/0001193125-23-211456.json","markdown":"https://secwatch.observer/filing/0001193125-23-211456.md","text":"https://secwatch.observer/filing/0001193125-23-211456.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523211456/0001193125-23-211456-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523211456/d497848d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T12:18:57.633026+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"af1f577181520fd1bdde364e876946016d73b744","claim":"Taysha Gene Therapies, Inc. reported financial results for the second quarter ended June 30, 2023.","evidence_excerpt":"On August 14, 2023, the Company reported financial results and business highlights for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523211456/0001193125-23-211456-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"f85f6dbaedecbb7b647f90efbafccbf343ea16bc","claim":"Taysha Gene Therapies, Inc. entered into Securities Purchase Agreement with certain institutional and other accredited investors valued at approximately $150.0 million (effective 2023-08-14).","evidence_excerpt":"On August 14, 2023, Taysha Gene Therapies, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain institutional and other accredited investors (the “ Purchasers ”), pursuant to which the Company agreed to sell and issue to the Purchasers in a private placement transaction (the “ Private Placement ”) (i) 122,412,376 shares (the “ Shares ”) of the Company’s common stock, par value $0.00001 (“ Common Stock ”), and (ii) with respect to certain Purchasers, pre-funded warrants to purchase 44,250,978 shares of Common Stock (the “ Pre-Funded Warrants ”) in lieu of Shares.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523211456/0001193125-23-211456-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional and other accredited investors"},{"label":"Value","value":"approximately $150.0 million"},{"label":"Effective","value":"2023-08-14"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}